Literature DB >> 24189458

MiR-101 functions as a tumor suppressor by directly targeting nemo-like kinase in liver cancer.

Qingyu Shen1, Hyun Jin Bae1, Jung Woo Eun1, Hyung Seok Kim1, Se Jin Park1, Woo Chan Shin1, Eun Kyung Lee2, Soha Park3, Won Sang Park1, Jung Young Lee1, Suk Woo Nam4.   

Abstract

Nemo-like kinase (NLK), an evolutionarily conserved MAP kinase-related kinase, has been reported to be involved in the development of hepatocellular carcinoma (HCC), but the underlying mechanisms leading to oncogenic NLK are poorly understood. A comprehensive microRNA (miRNA) profiling analysis on human HCC tissues identified four downregulated miRNAs that may target NLK. Ectopic expression of miRNA mimics suggested that miR-101 could suppress NLK in HCC cells. Notably, ectopic miR-101 expression repressed cancer cell growth and proliferation and imitated NLK knockdown effect on HCC cells. In conclusion, we suggest that miR-101 functions as a tumor suppressor by regulating abnormal NLK activity in liver.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Liver cancer; MiR-101; NLK; Tumor suppressor

Mesh:

Substances:

Year:  2013        PMID: 24189458     DOI: 10.1016/j.canlet.2013.10.030

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  31 in total

1.  miR-211 promotes non-small cell lung cancer proliferation by targeting SRCIN1.

Authors:  Leiguang Ye; Hui Wang; Baogang Liu
Journal:  Tumour Biol       Date:  2015-08-16

2.  MicroRNA-485-5p suppresses cell proliferation and invasion in hepatocellular carcinoma by targeting stanniocalcin 2.

Authors:  Guo-Xiao Guo; Quan-Ying Li; Wan-Li Ma; Zhao-Hui Shi; Xue-Qun Ren
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

Review 3.  The emerging role of Nemo-like kinase (NLK) in the regulation of cancers.

Authors:  Ying Huang; Yang Yang; Yong He; Jun Li
Journal:  Tumour Biol       Date:  2015-10-01

4.  Expression of Nemo-like kinase was increased and negatively correlated with the expression of TCF4 in lung cancers.

Authors:  Xiu-Wei Zhang; Song-Yan Chen; Dong-Wei Xue; Hui-Hui Xu; Lian-He Yang; Hong-Tao Xu; En-Hua Wang
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01

5.  Epstein-Barr virus-encoded microRNA BART1 induces tumour metastasis by regulating PTEN-dependent pathways in nasopharyngeal carcinoma.

Authors:  Longmei Cai; Yanfen Ye; Qiang Jiang; Yuxiang Chen; Xiaoming Lyu; Jinbang Li; Shuang Wang; Tengfei Liu; Hongbing Cai; Kaitai Yao; Ji-Liang Li; Xin Li
Journal:  Nat Commun       Date:  2015-07-02       Impact factor: 14.919

6.  By downregulating TIAM1 expression, microRNA-329 suppresses gastric cancer invasion and growth.

Authors:  Zheng Li; Xin Yu; Yang Wang; Jianxiong Shen; William Ka Kei Wu; Jinqian Liang; Fan Feng
Journal:  Oncotarget       Date:  2015-07-10

Review 7.  Role of MicroRNAs in Hepatocellular Carcinoma.

Authors:  Zixiang Zhu; Xiangle Zhang; Guoqing Wang; Haixue Zheng
Journal:  Hepat Mon       Date:  2014-08-01       Impact factor: 0.660

8.  MiR-216b is involved in pathogenesis and progression of hepatocellular carcinoma through HBx-miR-216b-IGF2BP2 signaling pathway.

Authors:  F-y Liu; S-j Zhou; Y-l Deng; Z-y Zhang; E-l Zhang; Z-b Wu; Z-y Huang; X-p Chen
Journal:  Cell Death Dis       Date:  2015-03-05       Impact factor: 8.469

9.  Metformin-induced suppression of Nemo-like kinase improves erythropoiesis in preclinical models of Diamond-Blackfan anemia through induction of miR-26a.

Authors:  Mark C Wilkes; Kavitha Siva; Gianluca Varetti; Jacqueline Mercado; Ethan P Wentworth; Cristina A Perez; Mallika Saxena; Sharon Kam; Simryn Kapur; Jun Chen; Anu Narla; Bert Glader; Shou Lin; Manuel Serrano; Johan Flygare; Kathleen M Sakamoto
Journal:  Exp Hematol       Date:  2020-09-12       Impact factor: 3.084

10.  Distinct anti-oncogenic effect of various microRNAs in different mouse models of liver cancer.

Authors:  Junyan Tao; Junfang Ji; Xiaolei Li; Ning Ding; Heng Wu; Yan Liu; Xin Wei Wang; Diego F Calvisi; Guisheng Song; Xin Chen
Journal:  Oncotarget       Date:  2015-03-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.